Pulmonary nocardiosis: A clinical analysis of 59 cases  by Kurahara, Yu et al.
Contents lists available at ScienceDirectRespiratory Investigation






shayashi@kch.hospjournal homepage: www.elsevier.com/locate/resinvOriginal articlePulmonary nocardiosis: A clinical analysis of 59 casesYu Kuraharaa, Kazunobu Tachibanaa,b, Kazunari Tsuyuguchib,
Masanori Akirac, Katsuhiro Suzukia,n, Seiji Hayashia
aDepartment of Internal Medicine, National Hospital Organization Kinki-Chuo Chest Medical Center, Osaka, Japan
bClinical Research Center, National Hospital Organization Kinki-Chuo Chest Medical Center, Osaka, Japan
cDepartment of Radiology, National Hospital Organization Kinki-Chuo Chest Medical Center, Osaka, Japana r t i c l e i n f o
Article history:
Received 15 August 2013
Received in revised form
5 September 2013
Accepted 26 September 2013









hor. Tel.: þ81 72 252 3021
yukurahara@kch.hosp.g
sp.go.jp (K. Tsuyuguchi),
.go.jp (S. Hayashi).a b s t r a c t
Background: Pulmonary nocardiosis is a rare but severe infection caused by Nocardia
species. This study aimed at describing the clinical characteristics and prognosis of
pulmonary nocardiosis.
Methods: An observational, retrospective study was undertaken of patients diagnosed with
pulmonary nocardiosis over a 13-year period at the Kinki-Chuo Chest Medical Center,
Osaka, Japan.
Results: Seven patients with airway nocardial colonization and 59 patients with pulmonary
nocardiosis were identiﬁed, one of whom had disseminated nocardiosis. Patients with
pulmonary nocardiosis were predominantly male patients (73%), with a mean age of 66 (range,
15–88) years. New-onset cough and dyspnea were the most common manifestations (76%).
Although 52 (88%) patients had at least one underlying pulmonary disease, most patients did
not appear to be systemically immunocompromised. The predominant abnormality on chest
computed tomography in pulmonary nocardiosis was airspace consolidation (52%), sometimes
associated with cavitation. Multivariate Cox proportional-hazards analysis revealed the follow-
ing signiﬁcant and independent risk factors for overall mortality: age 468 years (hazard ratio
[HR], 4.7; 95% conﬁdence interval [CI], 1.6–14; p¼0.05), pulmonary aspergillosis (HR, 8.8; 95% CI,
2.4–33; p¼0.01), and trimethoprim/sulfamethoxazole (TMP-SMZ) resistance (HR, 4.3; 95% CI, 1.6–
11; p¼0.04).
Conclusions: Clinicians should be aware that pulmonary nocardiosis can occur even in
immunocompetent patients, especially those with an underlying pulmonary disease. In
pulmonary nocardiosis, older age, pulmonary aspergillosis, and TMP-SMZ resistance are
associated with increased risk of mortality.
& 2013 The Japanese Respiratory Society. Published by Elsevier B.V. Open access under 
CC BY-NC-ND license.Society. Published by Elsevier B.V.
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The Nocardia genus of aerobic gram-positive bacteria causes a
range of infectious diseases, including isolated pulmonary
and skin infections and disseminated disease [1]. Pulmonary
nocardiosis is a rare but severe infection that commonly
presents as a subacute or chronic disease, mimicking lung
cancer or other pulmonary infections such as mycosis or
bacterial pneumonia. There are more than 90 Nocardia spe-
cies, at least 33 of which cause disease in humans [2].
Because of changes in taxonomy and the difﬁculty inher-
ent in the routine identiﬁcation of Nocardia strains at the
species level, there have been few published studies con-
cerning pulmonary nocardiosis [3–8]. Of those that have been
conducted, most have investigated only patients with immu-
nosuppression and have included only a small number of
patients. Moreover, the details of the clinical characteristics
and prognosis of pulmonary nocardiosis remain unclear. The
objective of the present study is to clarify the characteristics
of pulmonary nocardial patients and to elucidate the factors
that determine its etiology and prognosis.2. Materials and methods
2.1. Study Subjects
We aimed at studying the clinical pattern of pulmonary
nocardiosis in the Kinki-Chuo Chest Medical Center, Osaka,
Japan, based on a retrospective review of cases from January
1999 to October 2012. The hospital is a 450-bed respiratory
disease center designed to manage patients with various
respiratory diseases. In the present study, patients with no
evidence of pulmonary disease or symptoms of respiratory
infection despite the isolation of Nocardia species were
deﬁned as having airway nocardial colonization. Pulmonary
nocardiosis was deﬁned as the presence of symptoms of
respiratory infection consistent with pulmonary nocardiosis,
with Nocardia species isolated from respiratory sample cul-
tures on at least one occasion. Disseminated nocardiosis was
deﬁned as an infection in two noncontiguous organs or in
the central nervous system. This study was approved by
the Institutional Review Board at the Kinki-Chuo Chest
Medical Center (Approval date: November 14, 2011; Approval
number: 388).
2.2. Microbiological identiﬁcation
In order to diagnose pulmonary nocardiosis, samples were
examined microscopically after Gram staining in order to
determine the presence of microorganisms and establish
specimen quality. The presumptive identiﬁcation of Nocardia
species was based on the microscopic characteristics of the
isolates and the macroscopic morphology of the colonies.
Although 16S ribosomal RNA sequence-based identiﬁcation
of Nocardia species has recently become the gold standard,
this technology was not available in our laboratories during
the study period. Therefore, Nocardia isolates were identiﬁed
using a combination of traditional standard biochemicaltests, growth characteristics, and antimicrobial susceptibility
patterns. Hence, the microbiological notation was rendered in
its traditional form in this study. The susceptibility of the
isolates was determined by the disc diffusion method. A total
of 90 specimens from 66 patients were identiﬁed as culture-
proven Nocardia.
2.3. Radiographic assessment
Three pulmonary infectious disease experts (Y.K., K. Tachi-
bana., and K.S.) and one chest radiologist (M.A.) retrospec-
tively reviewed de-identiﬁed computed tomography (CT)
ﬁlms. The reviewers classiﬁed each case based on the
presence of the following features: (1) airspace consolidation;
(2) nodules (deﬁned as those with diameters o3 cm); (3)
cavity; (4) consolidation with cavity; (5) pleural effusion; and
(6) indeterminate (we anticipated the possibility that some
cases had an underlying pulmonary condition indistinguish-
able from pulmonary nocardiosis because of the complicated
structure of lung ﬁelds). Any inconsistencies were resolved by
consensus.
2.4. Study variables
The following data were collected: patient demographics,
comorbidities, immunological state, clinical manifestations,
radiographic ﬁndings, bacteriological reports, susceptibility
to trimethoprim/sulfamethoxazole (TMP-SMZ), treatment course,
and survival time from diagnosis.
2.5. Statistical analysis
Statistical analysis was performed with SPSS version 15.0J
software (SPSS Inc., Chicago, Illinois), and the Kaplan–Meier
method was used for survival analysis. If the patient died or
was lost to follow-up during the study period, this was
recorded as censored data. A univariate assessment of
selected risk factors was performed using a Cox proportional
hazard model. To eliminate confounding factors in predicting
mortality risk, variables with P values o0.05 on univariate
analysis were then entered into a multivariate assessment.
We used a Cox proportional hazard model with a step-up
procedure, utilizing the likelihood ratio as the criterion for
adding signiﬁcant variables. Results are expressed as hazard
ratios with corresponding 95% conﬁdence intervals (CI). A P
value of o0.05 was regarded as signiﬁcant.3. Results
3.1. Characteristics and clinical features of the patients
A total of 90 respiratory specimens from 66 patients were
identiﬁed as culture-proven Nocardia. Seven patients were
diagnosed with airway nocardial colonization because they
had minimal or no lung-ﬁeld lesions and the absence of
respiratory symptoms. These lesions remained stable after at
least 1 year of follow-up, during which time no treatment was
given. In total, 59 patients were diagnosed with pulmonary
nocardiosis (43 male patients and 16 female patients). One
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system.
The characteristics and underlying diseases of patients with
airway nocardial colonization and pulmonary nocardiosis are
detailed in Table 1. The mean age was 66 years (range, 15–88
years). A total of 55 (93%) of 59 patients had at least one
underlying pulmonary disease. Pre-existing structural abnorm-
alities of the lung were common. Notably, most patients did not
appear to be immunocompromised. Only one patient was being
treated with corticosteroids (for systemic vasculitis); no other
patient was receiving immunosuppressive agents. No patient
had undergone transplantation, and no patient had human
immunodeﬁciency virus infection or were alcoholic. All patients
with airway nocardial colonization were male patients, and their
mean age was 71 years.3.2. Symptoms, laboratory data, and radiographic
patterns
At the time when Nocardia infection was identiﬁed, 45
patients with pulmonary nocardiosis (76%) had new-onset
cough and dyspnea, which was associated with a fever higher
than 37.5 1C in 36 patients (61%). In one case, dissemination
to the central nervous system was detected, and that patient












Underlying condition 4 (57) 55 (93)
Non-pulmonary
underlying condition
1 (14) 12 (20)
Cardiovascular diseases 1 (14) 5 (8.5)




Hepatic diseases 0 1 (1.7)
Renal failure 0 1 (1.7)
Pulmonary underlying
condition
3 (43) 52 (88)
Chronic obstructive
pulmonary disease
1 (14) 13 (22)
Pulmonary malignancy 1 (14) 12 (20)







Pulmonary aspergillosis 0 6 (10)
Bronchiectasis 1 (14) 6 (10)
Othersa 0 3 (5.1)
Data are presented as mean7SD or n (%).
a Includes bronchial asthma, idiopathic pulmonary ﬁbrosis, and
chronic hypersensitivity pneumonitis.leukocytosis in 20 patients (34%) and elevated C-reactive
protein levels in 43 patients (73%).
Radiographic ﬁndings in the present study are given in
Table 2. The predominant abnormality on chest CT was
airspace consolidation (Fig. 1), which may have been asso-
ciated with cavitation. The second predominant abnormality
was the presence of nodules (Fig. 2). Because a majority (88%)
of the patients had at least one baseline pulmonary disease,
radiographic patterns were indeterminate in 12 patients
(20%). For example, mixed active infection with other organ-
isms (such as Aspergillus species or Mycobacterium species)
resulted in a radiographic appearance indistinguishable from
that of pulmonary nocardiosis. All patients with airway
nocardial colonization had tiny nodules in the lung ﬁelds,
and these nodules persisted for at least 1 year of follow-up in
the absence of treatment.3.3. Microbiological identiﬁcation
In the present study, microbiological notation was rendered
in its traditional form. Because Nocardia taxonomy was under
continuous revision during the study period, we were not
able to re-identify all of the Nocardia species using 16S
ribosomal RNA sequence analysis. The species isolated from
the respiratory samples in the present study were the
following: Nocardia asteroides (40 patients [68%]), Nocardia
farcinica (six patients [10%]), Nocardia nova (six patients
[10%]), Nocardia otitidiscaviarum (four patients [6.8%]), and
Nocardia brasiliensis (three patients [5.1%]). Infection was
polymicrobial in 17 cases (30%), with the following organisms:
Aspergillus fumigatus (four patients [6.8%]), Aspergillus niger
(two patients [3.4%]), Mycobacterium tuberculosis (two patients
[3.4%]), Mycobacterium avium complex (six patients [10%]), and
Mycobacterium kansasii (three patients [5.1%]). Thirty-six (61%)
patients were treated with TMP-SMZ (Table 3). Sixteen
patients (27%) had contracted TMP-SMZ-resistant Nocardia
infection: speciﬁcally, those with N. farcinica (5 of 6), N.
otitidiscaviarum (4 of 4), and N. asteroides infection (7 of 40).
Most patients infected with TMP-SMZ-resistant pathogens
were treated with imipenem/cilastatin (Table 1).Table 2 – Radiographic (computed tomography) presen-
tations among patients with airway nocardial coloniza-













Cavity 0 2 (3.4)
Pleural effusion 0 1 (1.7)
Indeterminatea 0 12 (20)
Total 7 (100) 59 (100)
a Underlying pulmonary condition indistinguishable from pul-
monary nocardiosis.
Fig. 1 – A 66-year-old man with pulmonary nocardiosis and idiopathic pulmonary ﬁbrosis. Left: initial computed tomography
(CT) scan shows bilateral subpleural reticulation and cystic lesions. Right: CT scan, obtained when the patient developed high-
grade fever and cough, shows consolidation with air bronchogram in the left upper lobe.
Fig. 2 – A 77-year-old man with pulmonary nocardiosis and silicosis. Left: initial computed tomography (CT) scan shows
bilateral small nodules consistent with silicosis. Right: CT scan, obtained when the patient developed cough and yellow
sputum, shows nodules in the right lower lobe.
Table 3 – Trimethoprim–sulfamethoxazole susceptibility
and treatment among patients with airway nocardial






Susceptible 7 (100) 43 (73)
Resistant 0 16 (27)
Treatment




Meropenem – 2 (3.4)
Minocycline – 2 (3.4)
Surgery – 2 (3.4)
Othersa – 3 (5.1)
Data are presented as n (%).
a Includes ceftriaxone, linezolid, and amikacin. TMP/
SMZ¼trimethoprim/sulfamethoxazole.
Fig. 3 – Kaplan–Meier estimates of overall survival in
patients with pulmonary nocardiosis. Survival was
calculated from the day of ﬁrst diagnosis of the infection.
Data were censored at the end of the follow-up period or at
the time of death.
r e s p i r a t o r y i n v e s t i g a t i o n 5 2 ( 2 0 1 4 ) 1 6 0 – 1 6 6 1633.4. Risk factors
Survival rates from the date of diagnosis of pulmonary nocar-
diosis were 97% at 30 days, 83% at 90 days, and 74% at 180 days
(Fig. 3). To determine the risk factors associated with mortality,
we analyzed the data using Cox proportional hazard regression
modeling. After univariate analysis, ﬁve signiﬁcant risk factors(po0.05) for mortality were identiﬁed: a history of heavy smoking
(Brinkman index 4428), age 468 years, pulmonary malignancy,
pulmonary aspergillosis, and TMP-SMZ resistance (Table 4).
These signiﬁcant risk factors identiﬁed by univariate analysis
were then entered into multivariate analysis using a Cox propor-
tional hazard regression model. The risk factors independently
associated with overall mortality were age 468 years (hazard
ratio [HR], 4.7; 95% conﬁdence interval [CI], 1.6–14; p¼0.05),
pulmonary aspergillosis (HR, 8.8; 95% CI, 2.4–33; p¼0.01), and
TMP-SMZ resistance (HR, 4.3; 95% CI, 1.6–11; p¼0.04) (Table 5).
Table 4 – Univariate analysis of risk factors for overall mortality among patients with pulmonary nocardiosis.
Hazard ratio (95% CI) P value
Brinkman index 4428 3.0 (1.2–8.4) 0.020n
Age 468 years 3.6 (1.4–10.2) 0.0057n
Pneumoconiosis 0.43 (0.068–1.5) 0.21
Healed or active pulmonary tuberculosis 0.66 (0.15–2.0) 0.49
Pulmonary aspergillosis 3.6 (1.0–11) 0.048n
TMP/SMZ resistance 2.8 (1.1–6.5) 0.029n
CI¼conﬁdence interval; TMP/SMZ¼trimethoprim/sulfamethoxazole.
n Statistically signiﬁcant value (po0.05).
Table 5 – Multivariate analysis of risk factors for overall mortality among patients with pulmonary nocardiosis.a
Hazard ratio (95% CI) P value
Brinkman index 4428 2.2 (0.8–6.6) 0.11
Age 468 years 4.7 (1.6–14) 0.005†
Pulmonary aspergillosis 8.8 (2.4–33) 0.001†
TMP/SMZ resistance 4.3 (1.6–11) 0.004†
CI¼conﬁdence interval; TMP/SMZ¼trimethoprim/sulfamethoxazole.
† Statistically signiﬁcant value (po0.05).
a Adjusted for pulmonary malignancy.
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The present study describes the characteristics of patients with
pulmonary nocardiosis and the factors associated with a poor
prognosis. Although there have been some studies of pulmonary
nocardiosis, they have generally dealt with small numbers of
cases [3–8]. To our knowledge, ours is the largest study of
pulmonary nocardiosis that includes clinical characteristics
and prognostic factors. Our ﬁndings that older age, pulmonary
aspergillosis, and TMP-SMZ resistance are independent and
signiﬁcant risk factors for overall mortality have not previously
been reported in the published literature. Given the high
prevalence of underlying pulmonary diseases and the potential
impact of pulmonary nocardiosis, these ﬁndings have the
potential to greatly inﬂuence daily clinical practice.
Nocardia species are gram-positive aerobic bacilli that can
cause a wide variety of infections [1]. Their taxonomy is
under continuous revision; the ﬁnal identiﬁcation for each
species may require conﬁrmation by molecular techniques
such as 16S ribosomal RNA sequencing and polymerase chain
reaction analysis, which may change the initial biochemical
identiﬁcation. N. asteroides, formerly considered the most
common species associated with human disease, has
been redeﬁned as a complex that includes N. asteroides
sensu stricto, N. farcinica, N. nova, and Nocardia transvalensis
complex.
Most patients in the present study were male patients,
which is consistent with previously published reports [8,9].
Smoking status tended to be associated with higher mortal-
ity, but this was not signiﬁcant after multivariate analysis.
Smoking is a risk factor for a number of pulmonary infec-
tions, probably because of its adverse effects on respira-
tory defenses [10]. Patients older than 68 years also had a
higher risk of mortality, consistent with the increased riskassociated with pulmonary infection in elderly patients in
general [11]. The potential for immunosuppression in elderly
patients may contribute to the poorer outcomes in this group.
Generally, the use of immunosuppressants (such as those
used after solid organ transplantation and hematopoietic
stem cell transplantation) and corticosteroid therapies are
the main risk factors for nocardial infection [12]. However, a
US study found no evidence of underlying illness or immu-
nosuppressive treatment in 15% of patients with nocardiosis
[13]. It is clear, therefore, that pulmonary nocardiosis may
occur in non-immunocompromised patients. Although most
patients in the present study did not have any apparent
immunosuppression, 88% of patients had at least one under-
lying pulmonary disease; this was consistent with previous
studies of pulmonary nocardiosis [5–7]. In a previous study,
19% of patients with pulmonary nocardiosis had preexisting
structural abnormalities of the lung [14], and in the present
study, both pulmonary malignancy and aspergillosis were
associated with a higher risk of mortality. Although it is
conceivable that a poor cancer prognosis contributed to the
poor outcome of pulmonary nocardiosis, lung damage or
changes in the lung structure due to pulmonary malignancy
or aspergillosis may play an important role in nocardial
infection of the human airway. These pulmonary structural
abnormalities may be major risk factors for pulmonary
nocardiosis in non-immunocompromised patients. Other
pulmonary diseases such as chronic obstructive pulmonary
disease, pneumoconiosis, mycobacterial infection, and
bronchiectasis may also be risk factors for pulmonary nocar-
diosis, as previously reported [4,7,9,15–18], but these were not
signiﬁcant factors in the present study.
Microbiological ﬁndings showed that 27% of cultures
were resistant to TMP-SMZ, including most N. farcinica and
N. otitidiscaviarum isolates. Generally, N. farcinica is associated
with antibiotic resistance and poor outcomes [19,20]. However,
r e s p i r a t o r y i n v e s t i g a t i o n 5 2 ( 2 0 1 4 ) 1 6 0 – 1 6 6 165antimicrobial susceptibility patterns for this pathogen have
varied from one report to another [21,22]; it was recently
reported that problems exist in the inter-laboratory reproduci-
bility of TMP-SMZ susceptibility testing [23]. Hence, the choice
to not administer TMP-SMZ based on inaccurate susceptibility
results may be a real risk factor for overall mortality, rather
than TMP-SMZ resistance per se.
In the present study, the most common CT manifestations
of pulmonary nocardiosis were air-space consolidation and
nodules. Although there is no speciﬁc radiologic pattern for
pulmonary nocardiosis, nodules and cavities have commonly
been reported and may help when establishing the diagnosis
[5,24–28]. However, only two patients had cavitary lesions in
this study, possibly because most of our patients did not have
apparent immunosuppression (cavitation is especially com-
mon among immunosuppressed patients, such as those
infected with human immunodeﬁciency virus) [28,29]. More-
over, in the present study, all patients with the cavitary form
of pulmonary nocardiosis had mixed infection with Aspergil-
lus or Mycobacterium species. Thirteen patients were deemed
to have an indeterminate pattern, because the effects of the
co-infecting organisms were indistinguishable from those of
nocardiosis. Finally, most of the patients with pulmonary
nocardiosis had underlying pulmonary diseases, decreasing
the likely utility of radiographic ﬁndings in establishing the
diagnosis for pulmonary nocardiosis.
This study has some limitations that should be consid-
ered. First, this was a retrospective study, and as a result,
there are many potential biases which we were not able to
control. For example, our hospital was designed to manage
patients with complicated pulmonary diseases. Therefore,
most patients tended to have underlying pulmonary condi-
tions; this may not be the case in other hospitals. In our
population, no patient had apparent immunosuppression,
and only one patient had disseminated nocardiosis. A
second important limitation of the study is that molecular
technology was not available, meaning that we could not re-
identify Nocardia species that were initially identiﬁed more
than 10 years ago. Because the agreement between mole-
cular techniques and conventional methods ranges between
70% and 90% [30], reﬁning the classiﬁcation of Nocardia
species would not have substantially changed the main
outcomes of the present study. Therefore, the traditional
microbiological notation system was used in this study.
Third, due to underlying pulmonary conditions, there were
some difﬁculties in distinguishing nocardial airway coloni-
zation from pulmonary nocardiosis. We excluded patients
who had no symptoms of respiratory infection despite the
isolation of Nocardia species. Fourth, 12 patients with pul-
monary malignancy were included in the present study; the
majority of them died from their underlying malignancy.
Therefore, we believe that the adjustment for malignancy in
the multivariate analysis is appropriate, and will minimize
the effect of pulmonary malignancy on the prognosis of
pulmonary nocardiosis. Despite these limitations, our study
included the largest sample size of any study on pulmonary
nocardiosis published to date, and included detailed clin-
ical data. This study may help provide new information on
the risk factors for mortality in patients with pulmonary
nocardiosis.5. Conclusions
Pulmonary nocardiosis is not restricted to immunosup-
pressed patients. The disease can occur in immunocompe-
tent patients who have an underlying pulmonary disease,
with the most common being mycobacterial infection,
chronic obstructive pulmonary disease, and malignancy.
The predominant abnormality on chest CT in pulmonary
nocardiosis was airspace consolidation, which may have
been associated with cavitation. In patients with pulmonary
nocardiosis, older age, pulmonary aspergillosis, and TMP-
SMZ resistance were associated with higher mortality risk.
Clinicians should therefore be aware that pulmonary nocar-
diosis can occur even in non-immunosuppressed patients.Conﬂict of interest
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